Leading medical cannabis company AusCann
(ASX:AC8) has entered into a research agreement with Canadian group Jade Cannabis.
AusCann has engaged Jade Cannabis to undertake research and development work at its Canadian facility for an initial three-year period.
The company says the aim of the research is to obtain greater yield per square metre of grow room, resulting in more cost-effective cannabis pharmaceuticals for patients
Meantime, the company has appointed Canadian Luke Pigeau as its new Master Grower.
He was selected after an extensive global search and will oversee AusCann’s cultivation activities, accelerating AusCann’s Australian medical cannabis manufacturing operation.
Shares in AusCann
(ASX:AC8) closed flat at $1.26 on Friday.
